Back
Corporate News
Aarti Drugs’ revenue increased 19% to Rs 703.6 crore for the quarter ended June 30, 2026
01-Aug-2026, 06:19
Aarti Drugs Limited (NSE: AARTIDRUGS; BSE:524348) announced consolidated financial results for the quarter ended June 30, 2026, reporting total revenue of Rs 703.6 crore, a 19% year-over-year increase compared to Rs 590.8 crore in the prior year’s corresponding quarter. The company’s EBITDA rose to Rs 96.9 crore, a 30% increase year-over-year, with an EBITDA margin expansion of 120 basis points to 13.8%, while profit after tax stood at Rs 50.1 crore. Aarti Drugs’ Chief Financial Officer and Chief Operating Officer, Adhish Patil, noted a recovery in pricing environments and emphasized ongoing investments in capacity enhancement and backward integration, including expansion of oral solid dosage capabilities in Baddi, Himachal Pradesh.
Aarti Drugs Limited (NSE: AARTIDRUGS; BSE:524348) announced consolidated financial results for the quarter ended June 30, 2026, reporting total revenue of Rs 703.6 crore, a 19% year-over-year increase compared to Rs 590.8 crore in the prior year’s corresponding quarter. The company’s EBITDA rose to Rs 96.9 crore, a 30% increase year-over-year, with an EBITDA margin expansion of 120 basis points to 13.8%, while profit after tax stood at Rs 50.1 crore. Aarti Drugs’ Chief Financial Officer and Chief Operating Officer, Adhish Patil, noted a recovery in pricing environments and emphasized ongoing investments in capacity enhancement and backward integration, including expansion of oral solid dosage capabilities in Baddi, Himachal Pradesh.